[wp_ad_camp_4]Dextran-supplier Pharmacosmos extends its quality dextran offerings with DEAE-Dextran, manufactured in the company’s FDA and EDQM-approved facility in Denmark.
Holbæk, Denmark, July 14, 2015 – Pharmacosmos introduces DEAE-Dextran as part of the company’s extensive array of biopolymers for pharmaceutical use. The company sees the introduction as part of a dedicated continuing effort to developing and supplying its customers’ clinical grade dextran derivatives.
”Our DEAE-Dextran is graced with the same high quality as our other dextran products, and we believe that we, by introducing DEAE-Dextran as part of our already extensive portfolio, are able to build an even stronger position in the market,” said Dr Lars Christensen, CEO at Pharmacosmos.
Pharmacosmos plans to include a range of dextran derivatives in the near future. Furthermore, Pharmacosmos is also taking orders for custom-made production of specialty carbohydrates.
Pharmacosmos is the world leader in pharmaceutical dextran solutions and counts tailor-made solutions to special carbohydrate needs among its forces. The company is the only dextran provider approved by the US FDA and EDQM in Europe, and Pharmacosmos operates on the basis of an innovative and unique manufacturing process without the use of organic solvents.
About Dextran and DEAE-Dextran
DEAE-Dextran (Diethylaminoethyl-Dextran) is a polycatonic derivative of Dextran. DEAE-Dextran is used for a number of applications hereunder as vaccine adjuvant, in gene therapy, and protein stabilization.